ArticleFrontiers in immunology2026
Lupus nephritis and its association with subclinical myocardial alterations in systemic lupus erythematosus assessed by cardiovascular magnetic resonance.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Thyroid dysfunction risk in systemic lupus erythematosus: a systematic review of case-control studies.Frontiers in immunology · 2026Pooled it
- Myocarditis as the first sign of SLE: a case report and review of the literature.Rheumatology international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lupus nephritis (LN) is the most common and severe complication in patients with systemic lupus erythematosus (SLE) and is associated with cardiac disease. The purpose of this study was to assess the cardiac phenotype of SLE patients with LN using cardiovascular magnetic resonance (CMR), and to investigate whether comorbid LN is associated with left ventricular (LV) remodeling. Methods: Clinical assessment and CMR were performed in 66 SLE patients without LN, 36 SLE patients with LN, and 20 age- and sex-matched healthy subjects. Results: SLE patients with LN had a more impaired global longitudinal strain (-12.37 ± 5.15% vs. -14.40 ± 2.80% vs. -14.92 ± 3.04%; P = 0.045) than SLE patients without LN and control group. Moreover, native T1 (1330 ± 54 vs. 1286 ± 81 vs. 1256 ± 41; P<0.001), extracellular volume (ECV) (30.53 ± 4.57% vs. 28.34 ± 3.59% vs. 26.20 ± 3.03; P<0.001), and native T2 (43.69 ± 4.32 vs. 41.98 ± 3.66 vs. 39.60 ± 2.94; P<0.001) were higher in SLE patients with LN, intermediate in SLE patients without LN and lowest in control group. However, LV-LGE did not differ significantly between the SLE patients with or without LN (P > 0.05). In multivariable linear regression, LN status was associated with higher native T1 (β=0.244, P<0.05) and ECV values (β=0.224, P<0.05). Conclusions: SLE patients with LN showed more pronounced subclinical myocardial abnormalities on CMR. LN was an independent risk factor for cardiac impairment in patients with SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.